fbpx

Gilead Quarterly Revenue Rises on Remdesivir Sales

Gilead Quarterly Revenue Rises on Remdesivir Sales

Gilead Sciences Inc.’s revenue rose 17% in the third quarter, helped by sales of its antiviral drug remdesivir that has become a standard treatment fo

World watches as Biden takes over a ‘humbled’ U.S. struggling to contain its crises
Fox Books Quarterly Gains From News, Political Ads
Arizona gov elected chair of Republican Governors Association amid Trump’s criticism

Gilead Sciences Inc.’s revenue rose 17% in the third quarter, helped by sales of its antiviral drug remdesivir that has become a standard treatment for hospitalized Covid-19 patients.

Yet sales of the company’s other drugs were hurt by pandemic-related shutdowns. And the company dialed back its forecast for overall revenue this year because of lower-than-expected hospitalization rates of Covid-19 patients.

Remdesivir,…

This post first appeared on wsj.com

Do You Enjoy This Article?
Sign up for our newsletter and receive FREE access to download SuccessDigest Digital Weekly Edition for attainment of your financial freedom in the new digital economy!

Invalid email address
We promise not to spam you. You can unsubscribe at any time.

COMMENTS

WORDPRESS: 0
DISQUS: 0
%d bloggers like this: